tiprankstipranks
Advertisement
Advertisement
INmune Bio Expands Cord Tissue License for CORDStrom Platform
PremiumCompany AnnouncementsINmune Bio Expands Cord Tissue License for CORDStrom Platform
26d ago
INmune Bio announces new preclinical data for INB03
Premium
The Fly
INmune Bio announces new preclinical data for INB03
2M ago
Inmune Bio Earnings Call Balances Progress and Risk
Premium
Company Announcements
Inmune Bio Earnings Call Balances Progress and Risk
2M ago
INmune Bio Highlights CORDStrom RDEB Program and IP Strength
PremiumCompany AnnouncementsINmune Bio Highlights CORDStrom RDEB Program and IP Strength
3M ago
INmune Bio Advances XPro Toward Registrational Alzheimer’s Study
Premium
Company Announcements
INmune Bio Advances XPro Toward Registrational Alzheimer’s Study
3M ago
INmune Bio to Present New CORDStrom Phase III Data
Premium
Company Announcements
INmune Bio to Present New CORDStrom Phase III Data
3M ago
INmune Bio: Undervalued Pipeline with 2026 Clinical and Regulatory Catalysts Driving Buy Rating
PremiumRatingsINmune Bio: Undervalued Pipeline with 2026 Clinical and Regulatory Catalysts Driving Buy Rating
4M ago
INmune Bio outlines 2026 regulatory path in shareholder letter
Premium
Company Announcements
INmune Bio outlines 2026 regulatory path in shareholder letter
4M ago
INmune Bio CEO says ‘well positioned for continued execution’
Premium
The Fly
INmune Bio CEO says ‘well positioned for continued execution’
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100